Compare · EXEL vs IKNA

EXEL vs IKNA

Side-by-side comparison of Exelixis Inc. (EXEL) and Ikena Oncology Inc. (IKNA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both EXEL and IKNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • EXEL carries a market cap of $16.37B.
  • EXEL has hit the wire 7 times in the past 4 weeks while IKNA has been quiet.
  • EXEL has more recent analyst coverage (25 ratings vs 5 for IKNA).
MetricEXELIKNA
Company
Exelixis Inc.
Ikena Oncology Inc.
Price
-
-
Market cap
$16.37B
-
1M return
+7.83%
-
1Y return
+58.19%
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2000
2021
News (4w)
7
0
Recent ratings
25
5
EXEL

Exelixis Inc.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

IKNA

Ikena Oncology Inc.

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Latest EXEL

Latest IKNA